Rubius Therapeutics, Inc. Recorded Big Gain
Mon, Apr 25, 2022 at 05:30 PM
Rubius Therapeutics, Inc. (RUBY:NASDAQ) soared at $1.87, a gain of 40.6%. On Fri, Apr 22, 2022, RUBY:NASDAQ touched a New 2-Week Intraday Low of $1.18. The stock appeared on our News Catalysts scanner on Fri, Apr 08, 2022 at 01:09 PM in the 'BIOTECH' category. From Fri, Apr 08, 2022, the stock recorded 22.22% Up Days and 10.00% Green Days
About Rubius Therapeutics, Inc. (RUBY:NASDAQ)
Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.
Top 10 Gainers:
- Nkarta Inc. (NKTX:NASDAQ), 140.93%
- ION Geophysical Corporation (IO:NYSE), 46.29%
- Cango Inc. (CANG:NYSE), 40.68%
- Rubius Therapeutics, Inc. (RUBY:NASDAQ), 40.6%
- ERYTECH Pharma S.A. (ERYP:NASDAQ), 37.7%
- Redbox Entertainment Inc. (RDBX:NASDAQ), 37.54%
- Ardelyx, Inc. (ARDX:NASDAQ), 31.77%
- GWG Holdings, Inc. (GWGH:NASDAQ), 31.14%
- ImmuCell Corporation (ICCC:NASDAQ), 29.04%
- Veru Inc. (VERU:NASDAQ), 25.78%